ReviewCellular and molecular life sciences : CMLS2018
Gene therapy for chondral and osteochondral regeneration: is the future now?
Review in Cellular and molecular life sciences : CMLS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 46 citations in OpenAlex.
- Smart functionalized cartilage repair microspheres: Concepts and applications.Materials today. Bio · 2026Review
- Biomaterial-assisted gene therapy for bone repair.Materials today. Bio · 2026Review
- Non-viral gene delivery systems for osteoarthritis therapy.Biomaterials translational · 2026Review
- The evolving landscape of minimally invasive procedures in musculoskeletal diseases-part I.Frontiers in medicine · 2026Review
- A comprehensive review of curcumin-based scaffolds in cartilage tissue engineering.Stem cell research & therapy · 2025Review
- A Review of the Role of Bioreactors for iPSCs-Based Tissue-Engineered Articular Cartilage.Tissue engineering and regenerative medicine · 2023Review
- Review
- Timing Expression of miR203a-3p during OA Disease: Preliminary In Vitro Evidence.International journal of molecular sciences · 2023Article
- Integrated gradient tissue-engineered osteochondral scaffolds: Challenges, current efforts and future perspectives.Bioactive materials · 2023Review
- Translating musculoskeletal bioengineering into tissue regeneration therapies.Science translational medicine · 2022Review
- Engineering Closed-Loop, Autoregulatory Gene Circuits for Osteoarthritis Cell-Based Therapies.Current rheumatology reports · 2022Review
- CTGF as a multifunctional molecule for cartilage and a potential drug for osteoarthritis.Frontiers in endocrinology · 2022Review
- Advanced injectable hydrogels for cartilage tissue engineering.Frontiers in bioengineering and biotechnology · 2022Review
- A Review of the Use of Microparticles for Cartilage Tissue Engineering.International journal of molecular sciences · 2021Review
- Tissue Engineering Strategies to Increase Osteochondral Regeneration of Stem Cells; a Close Look at Different Modalities.Stem cell reviews and reports · 2021Review
- Osteochondral Tissue Engineering: The Potential of Electrospinning and Additive Manufacturing.Pharmaceutics · 2021Review
- Click chemistry-based pre-targeting cell delivery for cartilage regeneration.Regenerative biomaterials · 2021Article
- Update on Novel Non-Operative Treatment for Osteoarthritis: Current Status and Future Trends.Frontiers in pharmacology · 2021Review
- Multimodal approach to intraarticular drug delivery in knee osteoarthritis.Rheumatology international · 2020Review
- Emerging Gene-Editing Modalities for Osteoarthritis.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy might represent a promising strategy for chondral and osteochondral defects repair by balancing the management of temporary joint mechanical incompetence with altered metabolic and inflammatory homeostasis. This review analysed preclinical and clinical studies on gene therapy for the repair of articular cartilage defects performed over the last 10 years, focussing on expression vectors (non-viral and viral), type of genes delivered and gene therapy procedures (direct or indirect). Plasmids (non-viral expression vectors) and adenovirus (viral vectors) were the most employed vectors in preclinical studies. Genes delivered encoded mainly for growth factors, followed by transcription factors, anti-inflammatory cytokines and, less frequently, by cell signalling proteins, matrix proteins and receptors. Direct injection of the expression vector was used less than indirect injection of cells, with or without scaffolds, transduced with genes of interest and then implanted into the lesion site. Clinical trials (phases I, II or III) on safety, biological activity, efficacy, toxicity or bio-distribution employed adenovirus viral vectors to deliver growth factors or anti-inflammatory cytokines, for the treatment of osteoarthritis or degenerative arthritis, and tumour necrosis factor receptor or interferon for the treatment of inflammatory arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.